116 related articles for article (PubMed ID: 9121181)
41. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
42. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
[TBL] [Abstract][Full Text] [Related]
43. [Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].
Imai K; Yamanaka H; Kubota Y; Miki M; Ito T; Akaza H; Uchida K; Egawa S; Kuriyama M; Watanabe H; Okihara K; Kotake T; Usami M; Arai Y; Maeda H; Sagiyama K; Saito Y; Sakai H; Shida K
Hinyokika Kiyo; 1998 Oct; 44(10):755-63. PubMed ID: 9850846
[TBL] [Abstract][Full Text] [Related]
44. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
[TBL] [Abstract][Full Text] [Related]
45. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
[TBL] [Abstract][Full Text] [Related]
46. Prostate-specific antigen: critical issues for the practicing physician.
Ruckle HC; Klee GG; Oesterling JE
Mayo Clin Proc; 1994 Jan; 69(1):59-68. PubMed ID: 7505869
[TBL] [Abstract][Full Text] [Related]
47. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
[TBL] [Abstract][Full Text] [Related]
48. Prostate-specific antigen: update 1997.
Chan DW; Sokoll LJ
J Int Fed Clin Chem; 1997 Sep; 9(3):120-5. PubMed ID: 10174623
[TBL] [Abstract][Full Text] [Related]
49. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.
Sheikh M; Al-Saeed O; Kehinde EO; Sinan T; Anim JT; Ali Y
Int Urol Nephrol; 2005; 37(4):721-6. PubMed ID: 16362587
[TBL] [Abstract][Full Text] [Related]
50. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
51. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
52. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
53. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
[TBL] [Abstract][Full Text] [Related]
54. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
Bangma CH; Kranse R; Blijenberg BG; Schröder FH
Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
[TBL] [Abstract][Full Text] [Related]
55. The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma.
Demura T; Shinohara N; Tanaka M; Enami N; Chiba H; Togashi M; Ohashi N; Nonomura K; Koyanagi T
Cancer; 1996 Mar; 77(6):1137-43. PubMed ID: 8635135
[TBL] [Abstract][Full Text] [Related]
56. Individual prostate-specific antigen (PSA) forms as prostate tumor markers.
Becker C; Lilja H
Clin Chim Acta; 1997 Jan; 257(1):117-32. PubMed ID: 9028629
[TBL] [Abstract][Full Text] [Related]
57. The role of free prostate-specific antigen in prostate cancer detection.
Han M; Potter SR; Partin AW
Curr Urol Rep; 2000 May; 1(1):78-82. PubMed ID: 12084345
[TBL] [Abstract][Full Text] [Related]
58. Prostatic specific antigen for prostate cancer detection.
Nogueira L; Corradi R; Eastham JA
Int Braz J Urol; 2009; 35(5):521-9; discussion 530-2. PubMed ID: 19860930
[TBL] [Abstract][Full Text] [Related]
59. Age-specific reference ranges for serum prostate-specific antigen.
Richardson TD; Oesterling JE
Urol Clin North Am; 1997 May; 24(2):339-51. PubMed ID: 9126232
[TBL] [Abstract][Full Text] [Related]
60. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
Woodrum DL; Brawer MK; Partin AW; Catalona WJ; Southwick PC
J Urol; 1998 Jan; 159(1):5-12. PubMed ID: 9400426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
